Coherus Oncology Inc. has announced the publication of preclinical and clinical biomarker research on its investigational CCR8 antibody, tagmokitug (CHS-114), in the December 2025 issue of Molecular Cancer Therapeutics. The study demonstrates that tagmokitug exhibits high selectivity, picomolar binding affinity, and potent effector-mediated killing of CCR8+ cells, with no off-target binding observed. The research indicates that CCR8 is highly prevalent in many solid tumors and that tagmokitug selectively eliminates CCR8+ regulatory T cells without affecting other T cell subsets. Proof-of-mechanism was established in a first-in-human clinical study, with translational data showing selective reduction of CCR8+ Tregs in cancer patients. The results have been published and support the ongoing clinical evaluation of tagmokitug in combination with toripalimab for the treatment of solid tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9619309-en) on January 05, 2026, and is solely responsible for the information contained therein.